Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11084830 | 0.88 | MAPT (0.46) | KMT2AMEN1ATMPTGS2MAPT | |
| SCHEMBL5829385 | 0.85 | SRC (0.54) | KMT2AMEN1PTGS2MAPTL3MBTL1 | |
| Pirazolac SCHEMBL153631 | 0.81 | KDM4E (0.51) | KMT2AMEN1ATMPTGS2CDK2 | |
| SCHEMBL12869756 | 0.80 | PTGS2 (0.49) | KMT2AMEN1ATMPTGS2MAPT | |
| SCHEMBL11080583 | 0.80 | KDM4E (0.49) | KMT2AMEN1PTGS2MAPTRAB9A | |
| Pirazolac SCHEMBL10952997 | 0.80 | KDM4E (0.50) | KMT2AMEN1ATMPTGS2CDK2 | |
| SCHEMBL10876346 | 0.79 | RXRA (0.47) | KMT2AMEN1ATMPTGS2CDK2 | |
| SCHEMBL10879414 | 0.79 | PTGS2 (0.44) | KMT2AMEN1ATMPTGS2MAPT | |
| SCHEMBL10952988 | 0.78 | PTGS2 (0.43) | KMT2AMEN1ATMPTGS2MAPT | |
| Hydrochloric Acid SCHEMBL10948538 | 0.78 | RXRA (0.47) | KMT2AMEN1ATMPTGS2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154999-B1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX SA (FR) | 2009-04-15 | — | — | EP | claimed |
| EP-1363628-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2003-11-26 | — | — | EP | claimed |
| US-20030171393-A1 | Drugs for sex dysfunctions | NICOX S.A. (FR) | 2003-09-11 | — | — | US | claimed |
| CN-1342147-A | Nitrooxyderivatives having anti-inflammatory, analgesic and antithrombotic activity | NICOX SA (FR) | 2002-03-27 | — | — | CN | claimed |
| WO-2002011706-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | claimed |
| EP-1154999-B1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| US-20030171393-A1 | Drugs for sex dysfunctions | NICOX S.A. (FR) | 2003-09-11 | — | — | US | disclosed |
| US-6613784-B1 | Cyclooxygenase inhibitors such as 2-acetyloxybenzoic acid 6-(nitroxymethyl)-2-methylpyridinyl ester hydrochloride, having good kinetics, solubility and efficiency; nontoxic | NICOX S.A. (FR) | 2003-09-02 | — | — | US | disclosed |
| EP-1154999-A1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX S.A. (FR) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000051988-A1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX S.A. (FR) | 2000-09-08 | — | — | WO | disclosed |
| US-4952702-A | Process for the preparation of (1,4-diaryl-pyrazol-3-yl)-acetic acids | SEUREF A.G. (LI) | 1990-08-28 | — | — | US | disclosed |
| EP-0349919-A2 | Process for the preparation of (1,4-diaryl-pyrazol-3-yl)-acetic acids | SEUREF A.G. (LI) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171393-A1 | Drugs for sex dysfunctions | SRD5A1, SRD5A2, XDH | KMT2A 3142/4885MEN1 3582/4885ATM 2541/4885 |
| US-20030203899-A1 | Drugs for incontinence | PDE3A, NOS1, PDE3B | KMT2A 4301/4885MEN1 4367/4885ATM 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.